Skip to main content
SpringerLink
Log in

Economic Evaluation in Healthcare

A Brief History and Future Directions

  • Leading Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Over the last decade there has been tremendous interest in economic evaluations of healthcare programmes, especially in the pharmaceutical field. Economic evaluations started about 30 years ago as rather crude analyses, in which the value of improved health was measured in terms of increased labour production. Now, more refined methods are available to measure health changes in terms of quality-adjusted life-years gained or willingness to pay.

It is important to continue this development, and major fields for future work include the incorporation of quality-of-life measurements into economic evaluations and the linking of cost-effectiveness and cost-benefit analyses into a unified framework of economic evaluation. How to incorporate distributional issues is another important area. Finally, it seems crucial to further explore the link between economic evaluation and decision making, since the purpose of economic evaluations is to affect decision making.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Drummond M. Brandt A, Luce B. et al. Standardizing methodologies for economic evaluation in health care: practice problems and potential. Int J Technol Assess Health Care 1993; 9: 26–36

    Article  PubMed  CAS  Google Scholar 

  2. Drummond MF. Stoddard GL. Torrance GW. Methods for the economic evaluation of health care programs. Oxford: Oxford Medical Publications. 1987

    Google Scholar 

  3. Weisbrod B. Economics of public health: measuring the impact of diseases. Philadelphia: University of Pennsylvania Press, 1961

    Google Scholar 

  4. Torrance GW. Measurement of health state utilities for economic appraisal: a review. J Health Econ 1986; 5: 1–30

    Article  PubMed  CAS  Google Scholar 

  5. Johannesson M. Jonsson B. Economic evaluation in health care: is there a role for cost-benefit anaKsis? Health Policy 1991; 17: 1–23

    Article  PubMed  CAS  Google Scholar 

  6. Mishan EJ. Cost-benefit analysis. New York: Praeger, 1971

    Google Scholar 

  7. Dupuit JH. De la mesurc de Puulite des travaux publics. Annates des ponts et chaussees 1844. Trans., Barbaek RH. Int Econ Papers 1952; 17: 83–110

    Google Scholar 

  8. Kaldor N. Welfare propositions of economics and interpersonal comparisons of utility. Econ J 1939; 49: 549–552

    Article  Google Scholar 

  9. Hicks JR. The foundation of welfare economics. Econ J 1939; 49: 696–712

    Article  Google Scholar 

  10. Hicks JR. The four consumer’s surpluses. Rev Econ Stud 1941; 11: 31–41

    Google Scholar 

  11. Williams A. Cost-benefit analysis: bastard science? and/or insidious poison in the body politick? J Pub Econ 1972; 1: 199–225

    Article  Google Scholar 

  12. Dublin LI, Lotka AJ. The money value of a man. New York: Ronald Press, 1946

    Google Scholar 

  13. Becker GS. Human capital. Chicago: University of Chicago Press, 1964

    Google Scholar 

  14. Schelling TC. The life you save may be your own. In: Chase SB, editor. Problems in public expenditure analysis. Washington (DC): Brookings Institution, 1968

    Google Scholar 

  15. Mishan EJ. Evaluation of life and limb: a theoretical approach. J Polit Econ 1971; 79: 687–705

    Article  Google Scholar 

  16. Klarman HE, Francis JOS, Rosenthal G. Cost-effectiveness analysis applied to the treatment of chronic renal disease. Med Care 1968; 6: 48–54

    Article  Google Scholar 

  17. Weinstein MC, Zeckhauser R. Critical ratios and efficient allocation. J Public Econ 1973; 2: 147–157

    Article  Google Scholar 

  18. Johannesson M, Weinstein MC. On the decision rules of cost-effectiveness analysis. J Health Econ 1993; 12: 459–467

    Article  PubMed  CAS  Google Scholar 

  19. Bush JW, Chen M, Patrick DL. Cost-effectiveness using a health status index: analysis of the New York State PKU screening program. In: Berg R, editor. Health status indexes. Chicago: Hospital Research and Educational Trust, 1973

    Google Scholar 

  20. Weinstein MC, Stason WB. Hypertension: a policy perspective. Cambridge (Mass.): Harvard University Press, 1976

    Google Scholar 

  21. Pliskin JS, Shepard DS, Weinstein MC. Utility functions for life years and health status. Operations Res 1980; 28: 206–224

    Article  Google Scholar 

  22. Johannesson M, Pliskin JS, Weinstein MC. A note on QALYs, time tradeoff, and discounting. Med Decis Making 1994; 14: 188–193

    Article  PubMed  CAS  Google Scholar 

  23. Read JL, Quinn RJ, Berwick DM, et al. Preference for health outcomes: comparison of assessment methods. Med Decis Making 1984; 4: 315–329

    Article  PubMed  CAS  Google Scholar 

  24. Hornberger JC, Redelmeier DA, Peterson J. Variability among methods to assess patients’ well-being and consequent effect on a cost-effectiveness analysis. J Clin Epidemiol 1992; 45: 505–512

    Article  PubMed  CAS  Google Scholar 

  25. Viscusi WK. Fatal tradeoffs: public and private responsibilities for risk. New York: Oxford University Press, 1992

    Google Scholar 

  26. Cummings RG, Brookshire DS, Schulze WD. Valuing environmental goods. New Jersey: Rowman and Allanheld, 1986

    Google Scholar 

  27. Mitchell RC, Carson RT. Using surveys to value public goods: the contingent valuation method. Washington (DC): Resources for the Future, 1989

    Google Scholar 

  28. Bishop RC, Heberlein JA. Measuring values of extra market goods: are indirect measures biased? Am J Agric Econ 1979; 61: 926–930

    Article  Google Scholar 

  29. National Oceanic and Atmospheric Administration. Report of the NOAA panel on contingent valuation. Federal Register 1993; 58: 4602–4614

    Google Scholar 

  30. Hanemann MW. Welfare evaluations in contingent valuation experiments with discrete responses. Am J Agric Econ 1984; 66: 332–341

    Article  Google Scholar 

  31. Ciriacy-Wantrup SV. Capital returns from soil-conservation practices. J Farm Econ 1947; 29: 1181–1196

    Article  Google Scholar 

  32. Davis RK. Recreation planning as an economic problem. Nat Resour J 1963; 3: 239–249

    Google Scholar 

  33. Acton JP. Evaluating public programs to save lives: the case of heart attacks. Santa Monica: 1973. RAND Report: R-950-RC

  34. Thompson MS. Read JL, Liang M. Feasibility of willingness to pay measurement in chronic arthritis. Med Decis Making 1984; 4: 195–215

    Article  PubMed  CAS  Google Scholar 

  35. Thompson MS. Willingness to pay and accept risks to cure chronic disease. Am J Public Health 1986; 76: 392–396

    Article  PubMed  CAS  Google Scholar 

  36. Johannesson M, Jonsson B, Borgquist L. Willingness to pay for antihypertensive therapy: results of a Swedish pilot study. J Health Econ 1991; 10: 461–474

    Article  PubMed  CAS  Google Scholar 

  37. Johannesson M, Johansson P-O, Kristrom B, et al. Willingness to pay for antihypertensive therapy: further results. J Health Econ 1993; 12: 95–108

    Article  PubMed  CAS  Google Scholar 

  38. Golan EH, Shechter M. Contingent valuation of supplemental health care in Israel. Med Decis Making 1993; 13: 302–310

    Article  PubMed  CAS  Google Scholar 

  39. O’Brien B, Viramontes JL. Willingness to pay: a valid and reliable measure of health state preference? Med Decis Making 1994; 14: 289–297

    Article  PubMed  Google Scholar 

  40. Guyatt GH, Feeny DH, Patrick DL. Measuring health related quality of life. Ann Intern Med 1993; 118: 622–629

    PubMed  CAS  Google Scholar 

  41. Revicki DA, Kaplan RM. Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life. Qual Life Res 1993; 2: 477–487

    Article  PubMed  CAS  Google Scholar 

  42. Greene WH. Econometric analysis, 2nd ed. New York: MacMillan Publishing Company, 1993

    Google Scholar 

  43. Torrance GW, Boyle MH, Horwood SP. Application of multi-attribute utility theory to measure social preferences for health states. Oper Res 1982; 30: 1043–1069

    Article  PubMed  CAS  Google Scholar 

  44. Torrance GW, Furlong W, Feeny D, et al. Multi-attribute preference functions: health utilities index. PharmacoEconomics 1995; 7: 503–520

    Article  PubMed  CAS  Google Scholar 

  45. Feeny D, Furlong W, Boyle M, et al. Multi-attribute health status classification systems: health utilities index. PharmacoEconomics 1995; 7: 490–502

    Article  PubMed  CAS  Google Scholar 

  46. Sugden R, Williams A. The principles of practical cost-benefit analysis. Oxford: Oxford University Press, 1978

    Google Scholar 

  47. Williams A. Economics of coronary artery bypass grafting. BMJ 1985; 291: 326–329

    Article  PubMed  CAS  Google Scholar 

  48. Schulman KA, Kinosian B, Jacobson TA, et al. Reducing high blood cholesterol level with drugs: cost-effectiveness of pharmacologic management. JAMA 1990; 264: 3025–3033

    Article  PubMed  CAS  Google Scholar 

  49. Johannesson M. The relationship between cost-effectiveness analysis and cost-benefit analysis. Soc Sci Med 1995; 41: 483–489

    Article  PubMed  CAS  Google Scholar 

  50. Boadway RW, Bruce N. Welfare economics. Oxford: Blackwell, 1984

    Google Scholar 

  51. Wagstaff A. QALYs and the equity-efficiency trade-off. J Health Econ 1991; 10: 21–41

    Article  PubMed  CAS  Google Scholar 

  52. Henry D. Economic analysis as an aid to subsidization decisions: the development of Australian guidelines for pharmaceuticals. PharmacoEconomics 1992; 1: 54–67

    Article  PubMed  CAS  Google Scholar 

  53. Evans RG. Manufacturing consensus, marketing truth: guidelines for economic evaluation. Ann Intern Med 1995; 123: 59–60

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA

    Karen Blumenschein

  2. Centre for Health Economics, Stockholm School of Economics, Box 6501 S-113 83, Stockholm, Sweden

    Magnus Johannesson

Authors
  1. Karen Blumenschein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Magnus Johannesson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Magnus Johannesson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Blumenschein, K., Johannesson, M. Economic Evaluation in Healthcare. Pharmacoeconomics 10, 114–122 (1996). https://doi.org/10.2165/00019053-199610020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199610020-00003

Keywords

Search

Navigation